Xian Deng
Stock Analyst at UBS
(4.56)
# 997
Out of 5,060 analysts
89
Total ratings
62.6%
Success rate
16.4%
Average return
Main Sectors:
Stocks Rated by Xian Deng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintained: Buy | $1,400 | $818.63 | +71.02% | 36 | Oct 9, 2026 | |
| SWX: BIOV BioVersys AG | Reiterated: Buy | CHF 48.00 → CHF 47.00 | CHF 26.40 | +78.03% | 3 | Sep 10, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | €170.00 | €141.50 | +20.14% | 24 | Aug 3, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Hold | €30.00 | €25.88 | +15.92% | 4 | Apr 1, 2026 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 720.00 → CHF 605.00 | CHF 563.40 | n/a | 12 | Feb 6, 2023 | |
| FRA: MDG1 Medigene AG | Reiterated: Buy | €8.00 | €0.02 | n/a | 6 | Aug 4, 2022 | |
| AMS: CRBN Corbion N.V. | Reiterated: Buy | €31.00 | €22.02 | n/a | 4 | Nov 1, 2019 |
argenx SE
Oct 9, 2026
Maintained: Buy
Price Target: $1,400
Current: $818.63
Upside: +71.02%
BioVersys AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 48.00 → CHF 47.00
Current: CHF 26.40
Upside: +78.03%
Ipsen S.A.
Aug 3, 2026
Reiterated: Hold
Price Target: €170.00
Current: €141.50
Upside: +20.14%
Lakefront Biotherapeutics NV
Apr 1, 2026
Reiterated: Hold
Price Target: €30.00
Current: €25.88
Upside: +15.92%
Lonza Group AG
Feb 6, 2023
Reiterated: Buy
Price Target: CHF 720.00 → CHF 605.00
Current: CHF 563.40
Upside: n/a
Medigene AG
Aug 4, 2022
Reiterated: Buy
Price Target: €8.00
Current: €0.02
Upside: n/a
Corbion N.V.
Nov 1, 2019
Reiterated: Buy
Price Target: €31.00
Current: €22.02
Upside: n/a